Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 193 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: liothyronine Clear all
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 5, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

NCT07483307
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
Interventions
Neoadjuvant endocrine therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 5, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04105530
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions
Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 215 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

M6620 (VX-970) in Selected Solid Tumors

NCT03718091
View directory record Official record
Conditions
Solid Tumor, Leiomyosarcoma, Osteosarcoma
Interventions
M6620
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Pain Catastrophizing as a Cause for Systemic Inflammation

NCT00823147
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Pain Catastrophizing Induction
Behavioral
Lead sponsor
Beth Darnall, PhD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention

NCT05358366
View directory record Official record
Conditions
HIV Infections
Interventions
Infeccion de Amor (Love Infection)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 5, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Low Cylinder Toric

NCT00732030
View directory record Official record
Conditions
Cataracts
Interventions
Toric IOL (SN60T3)
Device
Lead sponsor
Alcon Research
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2010 · Synced Sep 5, 2026, 2:15 PM EDT
Not listed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

NCT05485207
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Liothyronine (T3) for Bipolar Depression

NCT00790738
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Liothyronine (T3), placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 5, 2026, 2:15 PM EDT
Active, not recruiting Phase 3 Interventional

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

NCT02215265
View directory record Official record
Conditions
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Interventions
Cisplatin, Postoperative radiotherapy
Drug · Radiation
Lead sponsor
Lisette Nixon
Government
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
3
States / cities
Redwood City, California • Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

NCT00136175
View directory record Official record
Conditions
Bladder Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep

NCT01169155
View directory record Official record
Conditions
Smoke Inhalation Injury, Burns
Interventions
Smoke Alarm Stimuli
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 84 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055
View directory record Official record
Conditions
Healthy
Interventions
1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Development and Evaluation to Reduce Disparities in Quality of Life for Latino Families Impacted by Cancer

NCT06622252
View directory record Official record
Conditions
Quality of Life, Pediatric Cancer, Caregiver Burden
Interventions
13-week session program
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 100 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

NCT00440362
View directory record Official record
Conditions
Influenza
Interventions
AVX502, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Sep 5, 2026, 2:15 PM EDT
Terminated Not applicable Interventional

Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals

NCT06654414
View directory record Official record
Conditions
Smoking Cessation, Depression, Anxiety, Nicotine Dependence, Gender Minority Stress
Interventions
PRIDE QUIT, Enhanced Treatment As Usual (ETAU)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 5, 2026, 2:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 5, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 5, 2026, 2:15 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Low-Dose Leptin and the Formerly-Obese

NCT00073242
View directory record Official record
Conditions
Obesity
Interventions
Leptin, Dietary modification, T3 repletion
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
19 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

NCT00311623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 5, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Initial Evaluation of the Cellie Coping Kit for Children With Injury

NCT03153696
View directory record Official record
Conditions
Injuries
Interventions
Cellie Coping Kit Intervention
Behavioral
Lead sponsor
Meghan Marsac
Other
Eligibility
8 Years to 12 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 5, 2026, 2:15 PM EDT